PsychedelicNewsBreaks Archive - Page 38 of 70

TuesdayNov 16, 2021 12:48 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) CEO Featured in Latest Episode of ‘Bell2Bell’ Podcast

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform committed to bringing science-backed benefits to all and reframing the psychedelic conversation, was featured in the latest episode of The Bell2Bell Podcast. Among other highlights of the interview, Delic CEO Matt Stang discussed the company’s network of businesses and the impact psychedelic research is having on the treatment of mental health. “We feel that the time is right now. The mental health crisis is sweeping not only this country but the world,” Delic Holdings CEO Matt Stang stated in the interview. “Last year, in America, we had four-times the…

TuesdayNov 16, 2021 9:30 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Strategic Appointment of World-Renowned Immunologist and Cytokine Expert

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has announced the appointment of Eleanor N. Fish, Ph.D., to its research and clinical advisory board. Dr. Fish is an accomplished researcher in the areas of immunology and inflammatory disorders and a member of the government of Canada’s expert scientific panel to the chief scientific advisor. She brings key expertise to FSD Pharma that will support the continued development of FSD-PEA, the company’s proprietary anti-inflammatory agent, and Lucid-MS, its drug candidate for the treatment of multiple sclerosis.…

MondayNov 15, 2021 12:45 pm

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Featured in Equity Research Report

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, was featured in a recent equity research report. The coverage, initiated by Maxim Group LLC, highlights MINDCURE’s efforts to set the stage to unlock value for the company. This includes work on its ongoing programs and clinical development, including synthetic ibogaine, for which it is planning a preclinical study with its research partner to initially conduct cardiac and neurological screens with data and potentially move into behavioral studies. In addition, the company plans to schedule a pre-IND meeting for its…

MondayNov 15, 2021 12:19 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Committed to Making Psychedelic Wellness Accessible to the Masses

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is well positioned to capitalize on the psychedelic industry’s continued growth trajectory. “The company owns and operates a self-sustaining ecosystem of businesses in the psychedelic space consisting of media, science and health business verticals. Delic has been particularly active on the mergers and acquisitions front over the last several months in a bid to further broaden the company’s business horizons,” reads a recent article. In March, the company acquired the brand and IP of Homestead, a legacy counterculture distributor of psychedelic media and creator of one of the first…

MondayNov 15, 2021 11:02 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q2 Financial Results, Business Highlights

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has released its unaudited second-quarter results and announced a conference call to review the report. The report covers the period ended Sept. 30, 2021. Highlights in the report included the company’s announcement of preclinical data for its novel deuterated psilocybin analog, CYB003, for the potential treatment of major depressive disorder and alcohol use disorder. The company has also been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency for its Boston-area research lab and has received FDA approval to proceed with a company-sponsored…

ThursdayNov 11, 2021 12:45 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Partnerships to Facilitate TRP-8803’s Advancement

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently announced a collaboration with researchers at the University of Wisconsin-Madison as part of preparations toward planned phase 2b studies. Under the partnership, Dr. Paul Hutson, PharmD, and Dr. Christopher Nicholas, Ph.D., will support clinical pharmacology studies for TRP-8803, Tryp’s proprietary drug formulation with a novel route of administration. Once completed, the studies will provide additional regulatory support for TRP-8803. The pair will also serve as investigators on a clinical pharmacology study to evaluate the safety and pharmacokinetics of TRP-8803. “This partnership is the latest in a series of collaborations with scholars, institutions and…

ThursdayNov 11, 2021 10:01 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) First-Ever Meet Delic Experience Ranks as World’s Largest Psychedelic and Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has released information regarding its inaugural Meet Delic event, which was held last week in Las Vegas. The company noted that the event was sold out, with more than 2,500 people in attendance, making the psychedelic edutainment experience and business expo the largest in the world. The event agenda featured 20 hours of talks, panels and discussions presented by more than 60 thought leaders, medical professionals and wellness advocates. The company has already released dates for the next year’s Meet Delic…

WednesdayNov 10, 2021 12:45 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) CMO to Participate in Horizons’ Veterans & Families Forum

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has announced that chief medical officer Dr. Rakesh Jetly will be part of the Horizons' Veterans & Families Forum. The forum is scheduled for Nov. 10, and Jetly will be a panel member for a presentation titled “The State of Care and the Case for Psychedelic Therapy.” The panel will begin at 7:30 p.m. The event is designed specifically for veterans and will be held in NYC at the Judson Memorial Church; a virtual webcast will…

TuesdayNov 09, 2021 10:38 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release Q2 2021 Financial Results, Host Call

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), is planning to release its Q2 2021 financial report on Nov. 15, 2021. The report will cover the period ended Sept. 30, 2021. The company is also planning on hosting a conference call and webcast the same day, which is scheduled to begin at 4:30 p.m. EST. The call will be hosted by Cybin CEO Doug Drysdale and will provide an overview of the financial results along with relevant business updates. In addition, Drysdale and other team members will answer questions during the call. Those who…

TuesdayNov 09, 2021 9:57 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Completion of Ketamine Wellness Centers Acquisition

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has completed the acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”). The completion firmly establishes Delic as the largest chain of wellness centers that provide ketamine treatments in the United States. Delic now offers access to new medicines and treatments through 12 operational clinics spread across 10 states, including Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, Utah. The company anticipates opening 15 additional clinics in the next 18 months. In addition, Kevin Nicholson, KWC CEO, was appointed chief operating officer at…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks